Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUZALLO vs ZYLOPRIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Management of signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy),Prevention of tumor lysis syndrome in patients receiving chemotherapy for leukemia, lymphoma, or solid tumor malignancies
Gout: management of chronic, primary, or secondary gout,Hyperuricemia associated with chemotherapy: prevention of acute uric acid nephropathy in patients with leukemia, lymphoma, and solid tumor malignancies receiving chemotherapy,Recurrent calcium oxalate calculi: prevention in patients with hyperuricosuria
Adults: 200 mg orally twice daily.
100-300 mg orally once daily, maximum 800 mg/day.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (prolonged to 48-72 hours in renal impairment). Clinical context: oxypurinol half-life determines dosing interval; dose adjustment required for Cr Cl < 20 m L/min.
Primarily metabolized by aldehyde oxidase to oxipurinol, the active metabolite. Also metabolized via xanthine oxidase. Bioactivation requires hepatic metabolism.
Allopurinol is metabolized primarily by aldehyde oxidase to its active metabolite, oxypurinol; both are excreted renally.
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Renal: allopurinol ~10% unchanged, oxypurinol ~70% unchanged; total renal elimination ~76% (allopurinol + oxypurinol); fecal/biliary: minor (~12-20% as allopurinol, ~3-5% as oxypurinol).
Approximately 95% bound primarily to albumin and alpha-1-acid glycoprotein.
Allopurinol: <1% bound; oxypurinol: ~17-20% bound (primarily to albumin).
Volume of distribution is 0.3–0.5 L/kg, indicating distribution primarily into extracellular fluid and well-perfused tissues.
Allopurinol: ~1.6 L/kg; oxypurinol: ~0.4-0.6 L/kg. Clinical meaning: allopurinol distributes widely into total body water, while oxypurinol has a smaller Vd consistent with limited tissue distribution.
Oral bioavailability is 60%–70% (first-pass metabolism); intravenous bioavailability is 100%.
Oral: allopurinol 67-90% (mean ~80%); oxypurinol formed via first-pass metabolism has an effective systemic exposure.
Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). No dose adjustment required for mild to moderate impairment (e GFR ≥ 30 m L/min/1.73 m²).
Cr Cl >60 m L/min: no adjustment; Cr Cl 30-60 m L/min: 200 mg daily; Cr Cl 10-30 m L/min: 100 mg daily; Cr Cl <10 m L/min: 100 mg every 2-3 days or 50 mg daily.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not recommended in moderate or severe hepatic impairment (Child-Pugh B or C).
No specific guidelines; use with caution in severe hepatic impairment.
Safety and efficacy not established in pediatric patients (< 18 years).
6-10 years: 150 mg/day; 11-16 years: 300 mg/day; <6 years: 50 mg/day; all given orally once daily.
No specific dose adjustment required; monitor renal function due to age-related decline.
Start at lower dose (100 mg daily) due to reduced renal function; titrate to achieve serum urate target.
There is no FDA black box warning for DUZALLO.
None
Hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis,Acute gout flare upon initiation; may require prophylactic anti-inflammatory therapy,Renal impairment: dose adjustment required,Hepatic toxicity may occur,Elevated risk of skin rash with concurrent amoxicillin or ampicillin use
Allopurinol hypersensitivity syndrome (AHS) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); increased risk in patients with HLA-B*5801 allele; renal impairment requires dose adjustment; use with caution in patients with liver dysfunction; may cause drowsiness or dizziness; discontinue at first sign of rash or other signs of hypersensitivity.
Hypersensitivity to allopurinol or any component of the formulation,Concomitant use with didanosine
Absolute: known hypersensitivity to allopurinol or any component of the formulation. Relative: concomitant use with didanosine; severe renal impairment (Cr Cl <10 m L/min) unless used for prevention of uric acid nephropathy during chemotherapy.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing elagolix levels. High-fat meals may slightly increase elagolix absorption but no dose adjustment needed. No other significant food interactions reported.
High-purine foods (e.g., organ meats, anchovies, sardines, mussels, beer) should be avoided as they increase uric acid levels. No significant food-drug interactions besides alcohol.
DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if clearly needed.
Allopurinol (Zyloprim) is a xanthine oxidase inhibitor. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: No known increased risk; use only if clearly needed. Overall FDA pregnancy category C.
Allopurinol and its metabolite oxypurinol are excreted into breast milk. M/P ratio: 1.4 for allopurinol, 2.5 for oxypurinol. No adverse effects reported in infants; compatible with breastfeeding, but monitor infant for rash.
Allopurinol and its metabolite oxypurinol are excreted into human breast milk. Milk-to-plasma ratio approximately 0.9-1.4 for allopurinol and 0.5-0.9 for oxypurinol. No adverse effects reported in infants. Considered compatible with breastfeeding given very low infant dose (<2% of maternal weight-adjusted dose).
No specific dose adjustments recommended for pregnancy. Monitor renal function; reduce dose if creatinine clearance decreases. Standard adult dosing: 100-300 mg/day, may be increased up to 800 mg/day under guidance.
No specific dose adjustment required during pregnancy. However, pregnancy can increase renal clearance; monitor serum uric acid levels and adjust dose if necessary. Maintain lowest effective dose.
DUZALLO (elagolix/estradiol/norethindrone acetate) is a Gn RH antagonist combination product for management of heavy menstrual bleeding in premenopausal women with uterine leiomyomas. Monitor bone mineral density with prolonged use beyond 6 months; avoid in patients with osteoporosis risk factors. Contraindicated with strong CYP3A4 inhibitors and in pregnancy. Assess for mood changes and depression. Use effective non-hormonal contraception during treatment.
Monitor serum uric acid levels monthly until goal is achieved; titrate every 2-4 weeks. Avoid use in acute gout flares; start after inflammation subsides. Check renal function and adjust dose accordingly (Cr Cl <30 m L/min: max 200 mg/day). Consider HLA-B*5801 screening in Han Chinese, Thai, or Korean patients to prevent severe hypersensitivity. Allopurinol hypersensitivity syndrome is rare but life-threatening; discontinue at first sign of rash. Concomitant azathioprine or 6-mercaptopurine requires dose reduction to 25-33% of original.
Take one tablet daily at approximately the same time with or without food.,Missing doses increases risk of pregnancy and reduces effectiveness for bleeding control.,Use effective non-hormonal contraception (e.g., condoms, copper IUD) during treatment and for 2 weeks after discontinuation.,Report severe headache, chest pain, or vision changes immediately (risk of thromboembolic events).,Notify your doctor if you suspect pregnancy or develop heavy bleeding, worsening depression, or jaundice.,Bone density may decrease; calcium and vitamin D supplementation is recommended.,Avoid grapefruit or grapefruit juice during treatment.
Take exactly as prescribed; do not miss doses.,Drink at least 8 glasses of water daily to prevent kidney stones.,Report rash, itching, or swelling immediately; may indicate severe allergic reaction.,Avoid alcohol, especially beer and liquor, which can increase uric acid.,Use with caution if you have kidney disease; your dose may need adjustment.,Do not start or stop other medications like diuretics without consulting your doctor.,This drug prevents gout attacks, so continue even if you feel well.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUZALLO vs ZYLOPRIM, answered by our medical review team.
DUZALLO is a Xanthine Oxidase Inhibitor that works by DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. ZYLOPRIM is a Xanthine Oxidase Inhibitor that works by Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUZALLO and ZYLOPRIM depend on the specific clinical indication. These are both Xanthine Oxidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUZALLO is: Adults: 200 mg orally twice daily.. The standard adult dose of ZYLOPRIM is: 100-300 mg orally once daily, maximum 800 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUZALLO and ZYLOPRIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUZALLO is classified as Category C. DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if. ZYLOPRIM is classified as Category C. Allopurinol (Zyloprim) is a xanthine oxidase inhibitor. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.